PE20070547A1 - Forma cristalina delta-d del clorhidrato de la ivabradina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen - Google Patents

Forma cristalina delta-d del clorhidrato de la ivabradina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen

Info

Publication number
PE20070547A1
PE20070547A1 PE2006001193A PE2006001193A PE20070547A1 PE 20070547 A1 PE20070547 A1 PE 20070547A1 PE 2006001193 A PE2006001193 A PE 2006001193A PE 2006001193 A PE2006001193 A PE 2006001193A PE 20070547 A1 PE20070547 A1 PE 20070547A1
Authority
PE
Peru
Prior art keywords
expressed
line
degrees
ivabradine hydrochloride
pharmaceutical compositions
Prior art date
Application number
PE2006001193A
Other languages
English (en)
Inventor
Stephane Horvath
Marie-Noelle Auguste
Gerard Damien
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36588996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070547(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20070547A1 publication Critical patent/PE20070547A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A LA FORMA CRISTALINA DELTA-D DEL CLORHIDRATO DE IVABRADINA (FORMULA I) QUE PRESENTA UN DIAGRAMA DE DIFRACCION X SOBRE POLVO CARACTERISTICO MEDIDO EN UN DIFRACTOMETRO PANALYTICAL X'PERT PRO CON UN DETECTOR X'CELERATOR, Y EXPRESADO EN TERMINOS DE POSICION DE LINEA (ANGULO DE BRAGG 2 THETA, EXPRESADO EN GRADOS), DE ALTURA DE LINEA EXPRESADA EN PUNTOS, DE SUPERFICIE DE LINEA EXPRESADA EN PUNTOS POR GRADOS, DE ANCHURA DE LINEA A MEDIA ALTURA EXPRESADA EN GRADOS Y DE DISTANCIA INTERRETICULAR d EXPRESADA EN Å. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO TIENE PROPIEDADES BRADICARDIZANTES Y LA FORMA CRISTALINA PRESENTA CARACTERISTICAS DE ESTABILIDA Y PROCESABILIDAD
PE2006001193A 2005-10-11 2006-10-02 Forma cristalina delta-d del clorhidrato de la ivabradina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen PE20070547A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0510354A FR2891827B1 (fr) 2005-10-11 2005-10-11 Forme cristalline deltad du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
PE20070547A1 true PE20070547A1 (es) 2007-07-07

Family

ID=36588996

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001193A PE20070547A1 (es) 2005-10-11 2006-10-02 Forma cristalina delta-d del clorhidrato de la ivabradina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen

Country Status (32)

Country Link
US (3) US7384932B2 (es)
EP (2) EP1775287A1 (es)
JP (1) JP2007112797A (es)
KR (1) KR20070040310A (es)
CN (1) CN1948293A (es)
AP (1) AP2185A (es)
AR (1) AR056573A1 (es)
AU (1) AU2006228028B2 (es)
BR (1) BRPI0604253A (es)
CA (1) CA2564369C (es)
CO (1) CO5840253A1 (es)
CR (1) CR8647A (es)
EA (1) EA010286B1 (es)
EC (1) ECSP066914A (es)
FR (1) FR2891827B1 (es)
GE (1) GEP20094654B (es)
GT (1) GT200600448A (es)
IL (1) IL178545A (es)
MA (1) MA28625B1 (es)
MX (1) MXPA06011767A (es)
MY (1) MY140490A (es)
NI (1) NI200600240A (es)
NO (1) NO20064588L (es)
NZ (1) NZ550436A (es)
PE (1) PE20070547A1 (es)
SA (1) SA06270371B1 (es)
SG (1) SG131857A1 (es)
TW (1) TW200800221A (es)
UA (1) UA90266C2 (es)
UY (1) UY29856A1 (es)
WO (1) WO2007042657A1 (es)
ZA (1) ZA200608404B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
EP2097383B1 (en) 2006-11-30 2012-02-08 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
CN101353325B (zh) * 2007-07-27 2011-11-09 上海优拓医药科技有限公司 稳定型盐酸伊伐布雷定结晶及其制备方法
US8212026B2 (en) 2007-05-30 2012-07-03 Ind-Swift Laboratories Limited Process for the preparation of ivabradine hydrochloride and polymorph thereof
WO2010072409A1 (en) 2008-12-22 2010-07-01 Krka, D. D., Novo Mesto Process for preparation of ivabradine
CN101768117B (zh) * 2008-12-29 2014-05-07 北京德众万全药物技术开发有限公司 一种盐酸伊伐布雷定晶型及其制备方法
CN101774969B (zh) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 硫酸伊伐布雷定及其i型结晶的制备方法
US8270169B2 (en) 2009-03-24 2012-09-18 Raytheon Company Translating hinge
WO2010128525A2 (en) 2009-05-04 2010-11-11 Dinesh Shantilal Patel A formulation of ivabradine for treating the cardiovascular disease
EP2902384B1 (en) 2010-02-12 2017-11-08 KRKA, D.D., Novo Mesto Form of ivabradine hydrochloride
HUP1000245A2 (en) 2010-05-07 2011-11-28 Richter Gedeon Nyrt Industrial process for the production ivabradin salts
WO2012025940A1 (en) * 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
CN102731400A (zh) * 2011-04-11 2012-10-17 山东新时代药业有限公司 一种盐酸伊伐布雷定的新晶型、制备方法及其在制备药物组合物中的用途
EP2726462B1 (en) 2011-08-02 2017-03-22 Sandoz AG Acetone solvate of ivabradine hydrochloride
WO2013064427A1 (en) 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
US9120755B2 (en) * 2011-11-14 2015-09-01 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
CN103012269B (zh) * 2013-01-05 2014-08-13 江苏宇田生物医药科技有限公司 一种盐酸伊伐布雷定晶型c及其制备方法
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
EP2781509B2 (en) 2013-03-19 2023-06-14 Chemo Research, S.L. New polymorph of ivabradine hydrochloride and method for its preparation
CZ305096B6 (cs) * 2013-10-02 2015-04-29 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice
ES2672472T3 (es) 2013-12-12 2018-06-14 Synthon Bv Composición farmacéutica que comprende ivabradina amorfa
EP2774606B1 (en) 2014-02-14 2019-01-30 Synthon B.V. Pharmaceutical composition comprising ivabradine hydrochloride polymorph IV
CN103880748B (zh) * 2014-04-03 2015-09-16 南京正大天晴制药有限公司 一种盐酸伊伐布雷定结构类似物及其制备方法和应用
CZ305436B6 (cs) 2014-07-10 2015-09-16 Zentiva, K.S. Pevná forma Ivabradin hydrochloridu a (R)-mandlové kyseliny a její farmaceutická kompozice
WO2016102423A1 (en) 2014-12-22 2016-06-30 Ratiopharm Gmbh Composition comprising ivabradine in a dissolved form
CN105503726B (zh) * 2015-12-30 2019-07-30 浙江美诺华药物化学有限公司 伊伐布雷定盐酸盐晶型变体delta-d的制备方法
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
TR201703066A2 (tr) 2017-02-28 2018-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi İvabradi̇ni̇n kati oral farmasöti̇k kompozi̇syonlari
CN107200710A (zh) * 2017-05-22 2017-09-26 苏州华健瑞达医药技术有限公司 盐酸伊伐布雷定新晶型、制备方法及含有其的组合物
IT202000025312A1 (it) * 2020-10-26 2022-04-26 Cambrex Profarmaco Milano S R L Processi per la preparazione di polimorfi di ivabradina hcl

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3119874A1 (de) * 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
DE3418270A1 (de) * 1984-05-17 1985-11-21 Dr. Karl Thomae Gmbh, 7950 Biberach Neue aminotetralinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9017453D0 (en) 1990-08-09 1990-09-26 Mcivor Robert C Fluid additive regulating apparatus
FR2681862B1 (fr) * 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
FR2868777B1 (fr) * 2004-04-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
FR2882554B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme critalline beta d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882556B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma d du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882555B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline gamma du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2882553B1 (fr) * 2005-02-28 2007-05-04 Servier Lab Forme cristalline beta du chlorhydrate de l'ivabradine, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
EP1958937A1 (fr) 2008-08-20
IL178545A (en) 2017-04-30
MY140490A (en) 2009-12-31
GEP20094654B (en) 2009-03-25
IL178545A0 (en) 2007-02-11
EA010286B1 (ru) 2008-08-29
SA06270371B1 (ar) 2010-03-08
CA2564369C (fr) 2010-06-15
US20080227771A1 (en) 2008-09-18
ECSP066914A (es) 2007-05-30
NO20064588L (no) 2007-04-12
EA200601661A1 (ru) 2007-04-27
WO2007042657A1 (fr) 2007-04-19
TW200800221A (en) 2008-01-01
CO5840253A1 (es) 2007-12-31
JP2007112797A (ja) 2007-05-10
CN1948293A (zh) 2007-04-18
SG131857A1 (en) 2007-05-28
US20070082886A1 (en) 2007-04-12
BRPI0604253A (pt) 2007-08-21
AR056573A1 (es) 2007-10-10
MXPA06011767A (es) 2007-04-10
ZA200608404B (en) 2008-06-25
CA2564369A1 (fr) 2007-04-11
NZ550436A (en) 2007-12-21
US7384932B2 (en) 2008-06-10
FR2891827B1 (fr) 2007-12-28
AU2006228028A1 (en) 2007-04-26
FR2891827A1 (fr) 2007-04-13
US20090318418A1 (en) 2009-12-24
CR8647A (es) 2007-06-08
UA90266C2 (ru) 2010-04-26
GT200600448A (es) 2007-05-21
EP1775287A1 (fr) 2007-04-18
MA28625B1 (fr) 2007-06-01
US7879841B2 (en) 2011-02-01
AP2185A (en) 2010-12-30
KR20070040310A (ko) 2007-04-16
AU2006228028B2 (en) 2011-08-25
UY29856A1 (es) 2006-11-30
AP2006003757A0 (en) 2006-10-31
NI200600240A (es) 2008-01-10

Similar Documents

Publication Publication Date Title
PE20070547A1 (es) Forma cristalina delta-d del clorhidrato de la ivabradina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen
CR8247A (es) FORMA CRISTALINA BETA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN
CR8248A (es) Forma cristalina beta del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que la contienen
AR056572A1 (es) FORMA CRISTALINA ð DEL CLOHIDRATO DE IVABRADINA,UN PROCEDIMIENTO PARA SU PREPARACION,COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN Y USOS EN TRASTORNOS CARDIOVASCULARES.
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
NO20081724L (no) Stabil farmasoytisk sammensetning omfattende et pyrimidin-sulfamid
WO2007048065A3 (en) Pyrimidinones as casein kinase ii (ck2) modulators
HRP20120323T1 (en) Diarylhydantoin compounds
AR056931A1 (es) Forma cristalina gamma d del clorhidrato de ivabradina, un procedimiento para su preparacion, composiciones farmaceuticas que la contienen, y usos en trastornos cardiovasculares
AR052926A1 (es) Forma cristalina gama del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones que la contienen
WO2008107478A8 (en) Quinolinone derivatives as parp and tank inhibitors
WO2007061360A3 (en) Novel 3-bicyclocarbonylaminopyridine-2-carboxamides or 3-bicyclocarbonylaminopyrazine-2-carboxamides
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
RS53209B (en) PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR
BRPI0909787A2 (pt) composição de moldagem termoplástica, usos da combinação de polieteraminas com óxidos amorfos, e de composições de moldagem trermoplásticas, fibra, folha ou moldagem, e, combinação dos componentes.
WO2007092642A3 (en) Polymer formulations of cetp inhibitors
WO2008009831A3 (fr) Derives de cyclodextrines amphiphiles
WO2008062476A3 (en) Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
MX2009003169A (es) Derivados de sulfonamida.
BRPI0417950A (pt) composições farmacêuticas
GEP20125392B (en) Tricyclic compounds and pharmaceutical use thereof
WO2009106599A3 (en) Substituted piperidines as therapeutic compounds
USD538830S1 (en) Magnifier
EP1850829A4 (en) NEW PROPOLFOL COMPOSITION WITH ASCORBIC ACID OR PHARMACEUTICALLY USEFUL SALTS

Legal Events

Date Code Title Description
FC Refusal